Aizen’s AI-native biotech teams up with San Diego Biopharma to pursue oral biologics, unlocking up to $100 million per target
Executive summary: Aizen Therapeutics entered a multi-program collaboration with San Diego Biopharma to develop oral biologics using its AI-native platform. The collaboration offers up to $100 million in revenue per target, highlighting the commercial potential of AI-enabled biologics and could accelerate innovation in oral drug delivery.
Who is involved: Aizen Therapeutics (AI-native biotech), San Diego Biopharma (public biotech based in San Diego).
Likely next: Further details on target selection, IND filings, and milestone payments are expected as the programs progress.
Aizen Therapeutics, an AI-native biotechnology company, announced a multi-program collaboration with San Diego Biopharma to advance oral biologics. The deal promises up to $100 million in revenue for each target, underscoring the financial upside of combining AI-driven drug discovery with biologics development. While the announcement highlights a potentially lucrative partnership, it does not disclose timelines, clinical stages, or regulatory steps involved.
Timeline
- — Secondhand book sales are booming. Is it because of AI? (BBC Technology)
- — KI: OpenAI-Umsatzchefin verlässt das Unternehmen (Handelsblatt)
- — Aizen Enters into Collaboration with San Diego Biopharma to Advance Oral Biologics (PR Newswire)
Analysis — what this means
Sectors affected
- oral biologics
- AI-native biotechnology
Sources
- Aizen Enters into Collaboration with San Diego Biopharma to Advance Oral Biologics — PR Newswire
- KI: OpenAI-Umsatzchefin verlässt das Unternehmen — Handelsblatt
- Secondhand book sales are booming. Is it because of AI? — BBC Technology
Related cases
- Nuix launches generally available generative AI tools for legal review, signaling broader AI-driven efficiency gains in the legal tech market
- Acer’s Vero 16 launch signals a push toward repairable, AI-enhanced laptops that align with tightening environmental regulations
- Inturai Ventures completes acquisition of DomeCommand, an AI-driven command-and-control platform for autonomous drone swarms, expanding its defense-tech portfolio
- Eluvio's Content Fabric and AI Video Intelligence selected by Cricket Australia to launch a global direct-to-consumer streaming service for live and archived cricket matches
- Exascend’s medical-grade storage deployment enables next-generation healthcare systems to handle intensive data workloads
- Top leisure travel agencies boost investment ahead of expected cruise surge and AI integration